Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QDEL Stock Forecast 2025-2026
$28.09
Current Price
$1.89B
Market Cap
Buy 4
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to QDEL Price Targets
+113.6%
To High Target of $60.00
+78.0%
To Median Target of $50.00
-11.0%
To Low Target of $25.00
QDEL Price Momentum
+14.4%
1 Week Change
-19.5%
1 Month Change
-29.1%
1 Year Change
-36.9%
Year-to-Date Change
-43.2%
From 52W High of $49.45
+18.2%
From 52W Low of $23.77
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Quidel (QDEL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on QDEL and similar high-potential opportunities.
Latest QDEL Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, QDEL has a neutral consensus with a median price target of $50.00 (ranging from $25.00 to $60.00). The overall analyst rating is Buy (7.3/10). Currently trading at $28.09, the median forecast implies a 78.0% upside. This outlook is supported by 4 Buy, 3 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Casey Woodring at JP Morgan, suggesting a 11.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QDEL Analyst Ratings
4
Buy
3
Hold
1
Sell
QDEL Price Target Range
Low
$25.00
Average
$50.00
High
$60.00
Current: $28.09
Latest QDEL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QDEL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | JP Morgan | Casey Woodring | Underweight | Maintains | $25.00 |
| Feb 13, 2025 | UBS | John Sourbeer | Neutral | Maintains | $45.00 |
| Feb 13, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $61.00 |
| Dec 11, 2024 | Citigroup | Patrick Donnelly | Buy | Upgrade | $50.00 |
| Dec 10, 2024 | Jefferies | Tycho Peterson | Hold | Initiates | $43.00 |
| Sep 19, 2024 | UBS | John Sourbeer | Neutral | Upgrade | $50.00 |
| Sep 5, 2024 | Craig-Hallum | Alexander Nowak | Buy | Upgrade | $57.00 |
| Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $61.00 |
| Aug 1, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $61.00 |
| May 9, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $68.00 |
| Mar 4, 2024 | UBS | John Sourbeer | Sell | Downgrade | $42.00 |
| Feb 14, 2024 | Craig-Hallum | Alexander Nowak | Hold | Downgrade | $0.00 |
| Feb 14, 2024 | William Blair | Andrew Brackmann | Market Perform | Downgrade | $0.00 |
| Feb 14, 2024 | JP Morgan | Casey Woodring | Underweight | Downgrade | $37.00 |
| Feb 14, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $81.00 |
| Feb 14, 2024 | Raymond James | Andrew Cooper | Outperform | Downgrade | $76.00 |
| Dec 21, 2023 | RBC Capital | Conor McNamara | Outperform | Maintains | $130.00 |
| Dec 11, 2023 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $72.00 |
| Nov 2, 2023 | Raymond James | Andrew Cooper | Strong Buy | Maintains | $100.00 |
| Sep 19, 2023 | RBC Capital | Conor McNamara | Outperform | Reiterates | $140.00 |
QuidelOrtho Corporation (QDEL) Competitors
The following stocks are similar to Quidel based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
QuidelOrtho Corporation (QDEL) Financial Data
QuidelOrtho Corporation has a market capitalization of $1.89B with a P/E ratio of 0.0x. The company generates $2.78B in trailing twelve-month revenue with a -73.7% profit margin.
Revenue growth is -4.7% quarter-over-quarter, while maintaining an operating margin of +6.6% and return on equity of -51.4%.
Valuation Metrics
Market Cap
$1.89B
Enterprise Value
$4.48B
P/E Ratio
0.0x
PEG Ratio
10.6x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
-4.7%
Gross Margin
+46.1%
Operating Margin
+6.6%
Net Margin
-73.7%
EPS Growth
-4.7%
Financial Health
Cash/Price Ratio
+5.3%
Current Ratio
1.2x
Debt/Equity
89.8x
ROE
-51.4%
ROA
+0.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
QuidelOrtho Corporation (QDEL) Business Model
About QuidelOrtho Corporation
What They Do
Manufacturer of diagnostic testing solutions.
Business Model
QuidelOrtho Corporation generates revenue by developing and selling a wide range of diagnostic testing products, including rapid tests, laboratory assays, and immunoassays. These products are utilized in various healthcare settings, such as hospitals and clinics, focusing on timely and accurate diagnosis to improve patient care.
Additional Information
The company plays a vital role in the healthcare sector, particularly during health crises, and is positioned to benefit from the growing demand for efficient diagnostic technologies across multiple medical areas, including infectious diseases and women's health.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
6,600
CEO
Mr. Brian J. Blaser
Country
United States
IPO Year
1992
Website
www.quidelortho.comQuidelOrtho Corporation (QDEL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why QuidelOrtho (QDEL) Could Beat Earnings Estimates Again
QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 24, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
QuidelOrtho Corporation (Nasdaq: QDEL) will report its Q1 2025 financial results on May 7, 2025, after market close, followed by a conference call.
Why It Matters
QuidelOrtho's upcoming financial results announcement may influence its stock performance, affecting investor sentiment and potential trading strategies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
QuidelOrtho (QDEL) has a strong earnings surprise history and favorable indicators suggesting a potential earnings beat in its upcoming quarterly report.
Why It Matters
QuidelOrtho's strong earnings surprise history and favorable conditions suggest potential for positive future performance, indicating possible stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
QuidelOrtho (QDEL) experienced significant trading volume recently, but recent earnings estimate revisions may hinder its short-term upward momentum.
Why It Matters
QuidelOrtho's increased trading volume signals heightened interest, but negative earnings estimate revisions may indicate potential weakness, affecting stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
QDEL is experiencing growth driven by its robust product portfolio.
Why It Matters
QDEL's growth signals robust demand and potential revenue increases, indicating strong market positioning and future profitability, which can positively influence stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
QDEL has launched the Results Manager System, aimed at improving diagnostic data management and enhancing efficiency in patient care.
Why It Matters
QDEL's Results Manager System could boost operational efficiency and patient outcomes, potentially increasing demand for its products and driving revenue growth, positively impacting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
QuidelOrtho® Introduces Results Manager™ System
1 month ago
Quick Summary
QuidelOrtho Corporation has launched the QuidelOrtho® Results Manager™ System, enhancing informatics capabilities for community hospitals and point-of-care settings in its diagnostics portfolio.
Why It Matters
QuidelOrtho's launch of the Results Manager System enhances its diagnostics portfolio, potentially increasing market share and revenue in a growing lab informatics market.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About QDEL Stock
What is QuidelOrtho Corporation's (QDEL) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, QuidelOrtho Corporation (QDEL) has a median price target of $50.00. The highest price target is $60.00 and the lowest is $25.00.
Is QDEL stock a good investment in 2025?
According to current analyst ratings, QDEL has 4 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $28.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QDEL stock?
Wall Street analysts predict QDEL stock could reach $50.00 in the next 12 months. This represents a 78.0% increase from the current price of $28.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is QuidelOrtho Corporation's business model?
QuidelOrtho Corporation generates revenue by developing and selling a wide range of diagnostic testing products, including rapid tests, laboratory assays, and immunoassays. These products are utilized in various healthcare settings, such as hospitals and clinics, focusing on timely and accurate diagnosis to improve patient care.
What is the highest forecasted price for QDEL QuidelOrtho Corporation?
The highest price target for QDEL is $60.00 from at , which represents a 113.6% increase from the current price of $28.09.
What is the lowest forecasted price for QDEL QuidelOrtho Corporation?
The lowest price target for QDEL is $25.00 from Casey Woodring at JP Morgan, which represents a -11.0% decrease from the current price of $28.09.
What is the overall QDEL consensus from analysts for QuidelOrtho Corporation?
The overall analyst consensus for QDEL is neutral. Out of 14 Wall Street analysts, 4 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $50.00.
How accurate are QDEL stock price projections?
Stock price projections, including those for QuidelOrtho Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 7:50 PM UTC